Characterisation of male breast cancer: a descriptive biomarker study from a large patient series

Matthew P. Humphries; Sreekumar Sundara Rajan; Hedieh Honarpisheh; Gabor Cserni; Jo Dent; Laura Fulford; Lee B. Jordan; J. Louise Jones; Rani Kanthan; Maria Litwiniuk; Anna Di Benedetto; Marcella Mottolese; Elena Provenzano; Sami  Shousha; Mark Stephens; Janina Kulka; Ian O. Ellis; Akinwale N Titloye; Andrew M. Hanby; Abeer M. Shaaban; Valerie  Speirs

doi:10.1038/srep45293

Characterisation of male breast cancer: a descriptive biomarker study from a large patient series

Matthew P. Humphries, Sreekumar Sundara Rajan, Hedieh Honarpisheh, Gabor Cserni, Jo Dent, Laura Fulford, Lee B. Jordan, J. Louise Jones, Rani Kanthan, Maria Litwiniuk, Anna Di Benedetto, Marcella Mottolese, Elena Provenzano, Sami Shousha, Mark Stephens, Janina Kulka, Ian O. Ellis, Akinwale N Titloye, Andrew M. Hanby, Abeer M. ShaabanValerie Speirs (Lead / Corresponding author)

Research output: Contribution to journal › Article › peer-review

46 Citations (Scopus)

233 Downloads (Pure)

Abstract

Male breast cancer (MBC) is rare. We assembled 446 MBCs on tissue microarrays and assessed clinicopathological information, together with data from 15 published studies, totalling 1984 cases. By immunohistochemistry we investigated 14 biomarkers (ERα, ERβ1, ERβ2, ERβ5, PR, AR, Bcl-2, HER2, p53, E-cadherin, Ki67, survivin, prolactin, FOXA1) for survival impact. The main histological subtype in our cohort and combined analyses was ductal (81%, 83%), grade 2; (40%, 44%), respectively. Cases were predominantly ERα (84%, 82%) and PR positive (74%, 71%), respectively, with HER2 expression being infrequent (2%, 10%), respectively. In our cohort, advanced age (>67) was the strongest predictor of overall (OS) and disease free survival (DFS) (p = 0.00001; p = 0.01, respectively). Node positivity negatively impacted DFS (p = 0.04). FOXA1 p = 0.005) and AR p = 0.009) were both positively prognostic for DFS, remaining upon multivariate analysis. Network analysis showed ERα, AR and FOXA1 significantly correlated. In summary, the principle phenotype of MBC was luminal A, ductal, grade 2. In ERα+ MBC, only AR had prognostic significance, suggesting AR blockade could be employed therapeutically.

Original language	English
Article number	45293
Pages (from-to)	1-9
Number of pages	9
Journal	Scientific Reports
Volume	7
DOIs	https://doi.org/10.1038/srep45293
Publication status	Published - 28 Mar 2017

Keywords

Journal article
Breast cancer
Tumour biomarkers

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/srep45293Licence: CC BY

Final Published Version
© The Author(s) 2017. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
Final published version, 524 KBLicence: CC BY

Cite this

Humphries, M. P., Sundara Rajan, S., Honarpisheh, H., Cserni, G., Dent, J., Fulford, L., Jordan, L. B., Jones, J. L., Kanthan, R., Litwiniuk, M., Di Benedetto, A., Mottolese, M., Provenzano, E., Shousha, S., Stephens, M., Kulka, J., Ellis, I. O., Titloye, A. N., Hanby, A. M., ... Speirs, V. (2017). Characterisation of male breast cancer: a descriptive biomarker study from a large patient series. Scientific Reports, 7, 1-9. Article 45293. https://doi.org/10.1038/srep45293

@article{fb8d6814f79e42e49175005128cdcd6c,

title = "Characterisation of male breast cancer: a descriptive biomarker study from a large patient series",

abstract = "Male breast cancer (MBC) is rare. We assembled 446 MBCs on tissue microarrays and assessed clinicopathological information, together with data from 15 published studies, totalling 1984 cases. By immunohistochemistry we investigated 14 biomarkers (ERα, ERβ1, ERβ2, ERβ5, PR, AR, Bcl-2, HER2, p53, E-cadherin, Ki67, survivin, prolactin, FOXA1) for survival impact. The main histological subtype in our cohort and combined analyses was ductal (81%, 83%), grade 2; (40%, 44%), respectively. Cases were predominantly ERα (84%, 82%) and PR positive (74%, 71%), respectively, with HER2 expression being infrequent (2%, 10%), respectively. In our cohort, advanced age (>67) was the strongest predictor of overall (OS) and disease free survival (DFS) (p = 0.00001; p = 0.01, respectively). Node positivity negatively impacted DFS (p = 0.04). FOXA1 p = 0.005) and AR p = 0.009) were both positively prognostic for DFS, remaining upon multivariate analysis. Network analysis showed ERα, AR and FOXA1 significantly correlated. In summary, the principle phenotype of MBC was luminal A, ductal, grade 2. In ERα+ MBC, only AR had prognostic significance, suggesting AR blockade could be employed therapeutically.",

keywords = "Journal article, Breast cancer , Tumour biomarkers",

author = "Humphries, {Matthew P.} and {Sundara Rajan}, Sreekumar and Hedieh Honarpisheh and Gabor Cserni and Jo Dent and Laura Fulford and Jordan, {Lee B.} and Jones, {J. Louise} and Rani Kanthan and Maria Litwiniuk and {Di Benedetto}, Anna and Marcella Mottolese and Elena Provenzano and Sami Shousha and Mark Stephens and Janina Kulka and Ellis, {Ian O.} and Titloye, {Akinwale N} and Hanby, {Andrew M.} and Shaaban, {Abeer M.} and Valerie Speirs",

note = "This study was funded by Yorkshire Cancer Research (grant L378). Breast Cancer Now (formerly Breast Cancer Campaign, grant 2007 MayPR02) provided funding for the accrual and construction of TMAs",

year = "2017",

month = mar,

day = "28",

doi = "10.1038/srep45293",

language = "English",

volume = "7",

pages = "1--9",

journal = "Scientific Reports",

issn = "2045-2322",

publisher = "Nature Publishing Group",

}

Humphries, MP, Sundara Rajan, S, Honarpisheh, H, Cserni, G, Dent, J, Fulford, L, Jordan, LB, Jones, JL, Kanthan, R, Litwiniuk, M, Di Benedetto, A, Mottolese, M, Provenzano, E, Shousha, S, Stephens, M, Kulka, J, Ellis, IO, Titloye, AN, Hanby, AM, Shaaban, AM & Speirs, V 2017, 'Characterisation of male breast cancer: a descriptive biomarker study from a large patient series', Scientific Reports, vol. 7, 45293, pp. 1-9. https://doi.org/10.1038/srep45293

TY - JOUR

T1 - Characterisation of male breast cancer

T2 - a descriptive biomarker study from a large patient series

AU - Humphries, Matthew P.

AU - Sundara Rajan, Sreekumar

AU - Honarpisheh, Hedieh

AU - Cserni, Gabor

AU - Dent, Jo

AU - Fulford, Laura

AU - Jordan, Lee B.

AU - Jones, J. Louise

AU - Kanthan, Rani

AU - Litwiniuk, Maria

AU - Di Benedetto, Anna

AU - Mottolese, Marcella

AU - Provenzano, Elena

AU - Shousha, Sami

AU - Stephens, Mark

AU - Kulka, Janina

AU - Ellis, Ian O.

AU - Titloye, Akinwale N

AU - Hanby, Andrew M.

AU - Shaaban, Abeer M.

AU - Speirs, Valerie

N1 - This study was funded by Yorkshire Cancer Research (grant L378). Breast Cancer Now (formerly Breast Cancer Campaign, grant 2007 MayPR02) provided funding for the accrual and construction of TMAs

PY - 2017/3/28

Y1 - 2017/3/28

N2 - Male breast cancer (MBC) is rare. We assembled 446 MBCs on tissue microarrays and assessed clinicopathological information, together with data from 15 published studies, totalling 1984 cases. By immunohistochemistry we investigated 14 biomarkers (ERα, ERβ1, ERβ2, ERβ5, PR, AR, Bcl-2, HER2, p53, E-cadherin, Ki67, survivin, prolactin, FOXA1) for survival impact. The main histological subtype in our cohort and combined analyses was ductal (81%, 83%), grade 2; (40%, 44%), respectively. Cases were predominantly ERα (84%, 82%) and PR positive (74%, 71%), respectively, with HER2 expression being infrequent (2%, 10%), respectively. In our cohort, advanced age (>67) was the strongest predictor of overall (OS) and disease free survival (DFS) (p = 0.00001; p = 0.01, respectively). Node positivity negatively impacted DFS (p = 0.04). FOXA1 p = 0.005) and AR p = 0.009) were both positively prognostic for DFS, remaining upon multivariate analysis. Network analysis showed ERα, AR and FOXA1 significantly correlated. In summary, the principle phenotype of MBC was luminal A, ductal, grade 2. In ERα+ MBC, only AR had prognostic significance, suggesting AR blockade could be employed therapeutically.

AB - Male breast cancer (MBC) is rare. We assembled 446 MBCs on tissue microarrays and assessed clinicopathological information, together with data from 15 published studies, totalling 1984 cases. By immunohistochemistry we investigated 14 biomarkers (ERα, ERβ1, ERβ2, ERβ5, PR, AR, Bcl-2, HER2, p53, E-cadherin, Ki67, survivin, prolactin, FOXA1) for survival impact. The main histological subtype in our cohort and combined analyses was ductal (81%, 83%), grade 2; (40%, 44%), respectively. Cases were predominantly ERα (84%, 82%) and PR positive (74%, 71%), respectively, with HER2 expression being infrequent (2%, 10%), respectively. In our cohort, advanced age (>67) was the strongest predictor of overall (OS) and disease free survival (DFS) (p = 0.00001; p = 0.01, respectively). Node positivity negatively impacted DFS (p = 0.04). FOXA1 p = 0.005) and AR p = 0.009) were both positively prognostic for DFS, remaining upon multivariate analysis. Network analysis showed ERα, AR and FOXA1 significantly correlated. In summary, the principle phenotype of MBC was luminal A, ductal, grade 2. In ERα+ MBC, only AR had prognostic significance, suggesting AR blockade could be employed therapeutically.

KW - Journal article

KW - Breast cancer

KW - Tumour biomarkers

U2 - 10.1038/srep45293

DO - 10.1038/srep45293

M3 - Article

C2 - 28350011

SN - 2045-2322

VL - 7

SP - 1

EP - 9

JO - Scientific Reports

JF - Scientific Reports

M1 - 45293

ER -

Characterisation of male breast cancer: a descriptive biomarker study from a large patient series

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this